• 1
    Buckley CD, Pilling D, Lord JM, Akbar AN, Scheel-Toellner D, Salmon M. Fibroblasts regulate the switch from acute resolving to chronic persistent inflammation [review]. Trends Immunol 2001; 22: 199204.
  • 2
    Heinrich PC, Behrmann I, Muller-Newen G, Schaper F, Graeve L. Interleukin-6-type cytokine signaling through the gp130/Jak/STAT pathway [review]. Biochem J 1998; 334: 297314.
  • 3
    Jones SA, Rose-John S. The role of soluble receptors in cytokine biology: the agonistic properties of the sIL-6R/IL-6 complex [review]. Biochim Biophys Acta 2002; 1592: 25163.
  • 4
    Nowell MA, Richards PJ, Horiuchi S, Yamamoto N, Rose-John S, Topley N, et al. Soluble IL-6 receptor governs IL-6 activity in experimental arthritis: Blockade of arthritis severity by soluble glycoprotein 130. J Immunol 2003; 171: 32029.
  • 5
    Nishimoto N, Yoshizaki K, Maeda K, Kuritani T, Deguchi H, Sato B, et al. Toxicity, pharmacokinetics and dose-finding study of repetitive treatment with humanized anti-interleukin-6 receptor antibody MRA in rheumatoid arthritis. J Rheumatol 2003; 30: 142635.
  • 6
    Samal B, Sun Y, Stearns G, Xie C, Suggs S, McNiece I. Cloning and characterization of the cDNA encoding a novel human Pre-B-Cell Colony-Enhancing Factor. Mol Cell Biol 1994; 14: 14317.
  • 7
    Ognjanovic S, Bao S, Yamamoto SY, Garibay-Tupas J, Samal B, Bryant-Greenwood GD. Genomic organization of the gene coding for human pre-B-cell colony-enhancing factor and expression in human fetal membranes. J Mol Endocrinol 2001; 26: 10717.
  • 8
    Ognjanovic S, Bryant-Greenwood GD. Pre-B-cell colony-enhancing factor, a novel cytokine of human fetal membranes. Am J Obstet Gynecol 2002; 187: 10518.
  • 9
    Ye SQ, Simon BA, Maloney JP, Zambelli-Weiner A, Gao L, Grant A, et al. Pre-B-Cell colony-enhancing factor as a potential novel biomarker in acute lung injury. Am J Respir Crit Care Med 2005; 171: 36170.
  • 10
    Jia SH, Li Y, Parodo J, Kapus A, Fan L, Rotstein OD, et al. Pre-B-cell colony-enhancing factor inhibits neutrophil apoptosis in experimental inflammation and clinical sepsis. J Clin Invest 2004; 113: 131827.
  • 11
    Fukuhara A, Matsuda M, Nishizawa K, Segawa K, Tanaka M, Kishimoto K, et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 2005; 307: 42630.
  • 12
    Turkson J, Ryan D, Kim JS, Zhang Y, Chen Z, Hauri E, et al. Phosphotyrosyl peptides block stat3-mediated DNA binding activity, gene regulation and cell transformation. J Biol Chem 2001; 276: 4544355.
  • 13
    Hufton SE, Moerkerk PT, Brandwijk R, de Bruine AP, Arends JW, Hoogenboom HR. A profile of differentially expressed genes in primary colorectal cancer using suppression subtractive hybridization. FEBS Lett 1999; 463: 7782.
  • 14
    Li FK, Davenport A, Robson R, Loetscher P, Rothlein R, Williams JD, et al. Leukocyte migration across human peritoneal mesothelial cells is dependent on directed chemokine secretion and ICAM-1 expression. Kidney Int 1998; 54: 217083.
  • 15
    McLoughlin RM, Hurst SM, Nowell MA, Harris DA, Horiuchi S, Morgan LW, et al. Differential regulation of neutrophil-activating chemokines by IL-6 and its soluble receptor isoforms. J Immunol 2004; 172: 567683
  • 16
    Darnell JE. STATs and gene regulation [review]. Science 1997; 277: 16305.
  • 17
    Nishimoto N, Yoshizaki K, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, et al. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum 2004; 50: 17619.
  • 18
    Richards PJ, Nowell MA, Horiuchi S, McLoughlin RM, Fielding CA, Grau S, et al. Functional characterization of a recombinant human soluble gp130 isoform and its therapeutic capacity in an experimental model of inflammatory arthritis. Arthritis Rheum 2006; 54: 166272.
  • 19
    Shouda R, Yoshida T, Hanada T, Wakioka T, Oishi M, Miyoshi K, et al. Induction of the cytokine signal regulator SOCS3/CIS3 as a therapeutic strategy for treating inflammatory arthritis. J Clin Invest 2001; 108: 17818.
  • 20
    Shahara S, Amin MA, Woods JM, Haines GK, Koch AE. Chemokine receptor expression and in vivo signaling pathways in the joints of rats with adjuvant-induced arthritis. Arthritis Rheum 2003; 48: 356883.
  • 21
    Krause A, Scaletta N, Ji JD, Ivashkiv LB. Rheumatoid arthritis synoviocyte survival is dependent on STAT3. J Immunol 2002; 169: 66106
  • 22
    Atsumi T, Ishihara K, Kamimura D, Ikushima H, Ohtani T, Hirota S, et al. A point mutation of Tyr-759 in interleukin 6 family cytokine receptor subunit gp130 causes autoimmune arthritis. J Exp Med 2002; 196: 97990.
  • 23
    Hurst SM, Wilkinson TS, McLoughlin RM, Jones S, Horiuchi S, Yamamoto N, et al. IL-6 and its soluble receptor orchestrate a temporal switch in the pattern of leukocyte recruitment seen during acute inflammation. Immunity 2001; 14: 70514.
  • 24
    Manicourt DH, Poilvache P, Van Egeren A, Devogelaer JP, Lenz ME, Thonar EJ. Synovial fluid levels of tumor necrosis factor α and oncostatin M correlate with levels of markers of the degradation of crosslinked collagen and cartilage aggrecan in rheumatoid arthritis but not in osteoarthritis. Arthritis Rheum 2000; 43: 2818.
  • 25
    Okamoto H, Yamamura M, Morita Y, Harada S, Makino H, Ota Z. The synovial expression and serum levels of interleukin-6, interleukin-11, leukemia inhibitory factor, and oncostatin M in rheumatoid arthritis. Arthritis Rheum 1997; 40: 1096105.
  • 26
    Heinrich P, Behrmann I, Haan S, Hermanns H, Muller-Newen G, Schaper F. Principles of interleukin (IL)-6-type cytokine signaling and its regulation [review]. Biochem J 2003; 374: 120.
  • 27
    Gearing D, Bruce A. Oncostatin M binds the high-affinity leukemia inhibitory factor receptor. New Biol 1992; 4: 615.
  • 28
    Auguste P, Guillet C, Fourcin M, Olivier C, Veziers J, Pouplard-Barthelaix A, et al. Signaling of type II oncostatin M receptor. J Biol Chem 1997; 272: 157604.
  • 29
    Diveu C, Lak-Hal A, Froger J, Ravon E, Grimaud L, Barbier F, et al. Predominant expression of the long isoform of GP130-like (GPL) receptor is required for interleukin-31 signaling. Eur Cytokine Netw 2004; 15: 291302.
  • 30
    Hermann JA, Hall MA, Maini RN, Feldmann M, Brennan FM. Important immunoregulatory role of interleukin-11 in the inflammatory process in rheumatoid arthritis. Arthritis Rheum 1998; 41: 138897.
  • 31
    Moreland L, Gugliotti R, King K, Chase W, Weisman M, Greco T, et al. Results of a phase-I/II randomized, masked, placebo-controlled trial of recombinant human interleukin-11 (rhIL-11) in the treatment of subjects with active rheumatoid arthritis. Arthritis Res 2001; 3: 24752.
  • 32
    Otero M, Lago R, Gomez R, Lago F, Dieguez C, Gomez-Reino JJ, et al. Changes in fat-derived hormones plasma concentrations: adiponectin, leptin, resistin, and visfatin in rheumatoid arthritis subjects. Ann Rheum Dis 2006. E-pub ahead of print.
  • 33
    Pope R. Apoptosis as a therapeutic tool in rheumatoid arthritis [review]. Nat Rev Immunol 2002; 2: 52735.
  • 34
    Ottonello L, Cutolo M, Frumento G, Arduino N, Bertolotto M, Mancini M, et al. Synovial fluid from patients with rheumatoid arthritis inhibits neutrophil apoptosis: role of adenosine and proinflammatory cytokines. Rheumatology 2002; 41: 124960.
  • 35
    Liu H, Pope R. The role of apoptosis in rheumatoid arthritis [review]. Curr Opin Pharmacol 2003; 3: 31722.
  • 36
    Koch AE. Chemokines and their receptors in rheumatoid arthritis: future targets? [review]. Arthritis Rheum 2005; 52: 710721.
  • 37
    Ognjanovic S, Ku T, Bryant-Greenwood G. Pre-B-cell colony-enhancing factor is a secreted cytokine-like protein from the human amniotic epithelium. Am J Obstet Gynecol 2005; 193: 273282.
  • 38
    Xu LG, Wu M, Hu J, Zhai Z, Slu HB. Identification of downstream genes upregulated by the tumor necrosis factor family member TALL-1. J Leukoc Biol 2002; 72: 4106.
  • 39
    Patrone L, Damore MA, Lee MB, Malone CS, Wall R. Genes expressed during the IFNγ-induced maturation of pre-B cells. Mol Immunol 2001; 38: 597606.
  • 40
    Chen MP, Chung FM, Chang DM, Tsai JC, Huang HF, Shin SJ, et al. Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus. J Clin Endocr Metab 2006; 91: 2959.
  • 41
    Martin PR, Shea R, Mulks MH. Identification of a plasmid-encoded gene from Haemophilus ducreyi which confers NAD independence. J Bacteriol 2001; 183: 116874.
  • 42
    Rongvaux A, Shea RJ, Mulks MH, Gigot D, Urbain J, Leo O, et al. Pre-B-cell colony-enhancing factor, whose expression is upregulated in activated lymphocytes, is a nicotinamide phosphoribosyltransferase, a cytosolic enzyme involved in NAD biosynthesis. Eur J Immunol 2002; 32: 322534.
  • 43
    Revollo JR, Grimm AA, Imai SI. The NAD biosynthesis pathway mediated by nicotinamide phosphoribosyltransferase regulates Sir2 activity in mammalian cells. J Biol Chem 2004; 279: 5075463.
  • 44
    Sestini S, Jacomelli G, Pescaglini M, Micheli V, Popucci G. Enzyme activities leading to NAD synthesis in human lymphocytes. Arch Biochem Biophys 2000; 379: 27782.
  • 45
    Hassman M, Schemainda I. FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for the induction of tumor cell apoptosis. Cancer Res 2003; 63: 743642.
  • 46
    Holen KD, Burk K, Schwartz GK, Spriggs D, Hollywood E, Ty V, et al. Dose-finding and pharmacokinetic study of FK866, an inhibitor of NAD biosynthesis [abstract]. Proc Am Soc Clin Oncol 2002; 21: A346.
  • 47
    Chaput M, Claes V, Portetelle D, Cludts I, Cravador A, Burny A, et al. The neurotrophic factor neuroleukin is 90% homologous with phosphohexose isomerase. Nature 998; 332: 45455.
  • 48
    Xu Q, Leiva MC, Fischkoff SA, Handschumacher RE, Lyttle CR. Leukocyte chemotactic activity of cyclophylin. J Biol Chem 1992; 267: 1196871.
  • 49
    Hoogewerg AJ, Leone JW, Reardon IM, Howe AJ, Asa D, Heinrikson RL, et al. CXC chemokines connective tissue activation peptide-III and Neutrophil activating peptide-2 are heparin/heparan sulfate-degrading enzymes. J Biol Chem 1995; 270: 326877.
  • 50
    Swope M, Sun H, Blake PR, Lolis E. Direct link between cytokine activity and a catalytic site for macrophage migration inhibitory factor. EMBO J 1998; 17: 353441.
  • 51
    Calandra T, Roger T. Macrophage Migration Inhibitory Factor: A regulator of innate immunity [review]. Nat Rev Immunol 2003; 3: 791800.
  • 52
    Kitani T, Okuno S, Fujisawa H. Growth phase-dependent changes in the subcellular localization of pre-B-cell colony-enhancing factor. FEBS Lett 2003; 544: 748.
  • 53
    Pyle M, Korbonits M, Guerorguiev M, Jordan S, Kola B, Morris D, et al. Macrophage migration inhibitory factor expression is increased in pituitary adenoma cell nuclei. J Endocrinol 2003; 176: 10310.
  • 54
    Leng L, Metz CN, Fang Y, Xu J, Donnelly S, Baugh J, et al. MIF signal transduction initiated by binding to CD74. J Exp Med 2003; 197: 146776.